NCT05930704
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SHR-2017 Injection in Postmenopausal Women
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SHR-2017 Injection Administered Subcutaneously to Postmenopausal Women
Suzhou Suncadia Biopharmaceuticals Co., Ltd.·Phase 1·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Osteoporosis
- Drug/Device/Intervention
- SHR-2017 injection
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Location
- Jinan, China
Timeline & enrollment
- Phase
- Phase 1
- Start date
- Jul 04, 2023
- End date
- Apr 12, 2025
- Enrollment
- 45 participants
Primary outcome
Number of participants with adverse events
Summary
The primary objective was to evaluate the safety and tolerability of SHR-2017 after a single
 subcutaneous (SC) injection in postmenopausal women
ICD-10 classifications
Osteoporosis, unspecifiedOther osteoporosisIdiopathic osteoporosisOsteoporosis in diseases classified elsewherePostmenopausal osteoporosis
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT05930704
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT05930704 through Pure Global AI's free database. This Phase 1 trial is sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. and is currently Recruiting. The study focuses on Osteoporosis. Target enrollment is 45 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.